Rui Avelar - Jan 24, 2022 Form 4 Insider Report for Evolus, Inc. (EOLS)

Role
Chief Medical Officer and Head of Research & Development
Signature
/s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar
Stock symbol
EOLS
Transactions as of
Jan 24, 2022
Transactions value $
$0
Form type
4
Date filed
1/26/2022, 08:02 PM
Previous filing
Aug 12, 2021
Next filing
Mar 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EOLS Common Stock Award $0 +53.6K +25.53% $0.00 263K Jan 24, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EOLS Stock Option (Right to Buy) Award $0 +77.6K $0.00 77.6K Jan 24, 2022 Common Stock 77.6K $5.46 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
F2 The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.

Remarks:

Chief Medical Officer and Head of Research & Development